<p>/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)（&#34;BioMarin&#34;）今天宣佈，計劃在市場和其他條件允許的情況下，發行 8.5 億美元的 2034 年到期的高級無擔保債券（&#34;債券&#34;）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/534018/BioMarin_Pharmaceutical_Inc_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/534018/BioMarin_Pharmaceutical_Inc_Logo.jpg"/></p>
<p>BioMarin 還宣佈，針對即將收購 Amicus Therapeutics, Inc.（&#34;Amicus&#34;）的交易（&#34;收購&#34;），啓動了一項新的 20 億美元高級擔保定期貸款&#34;B&#34;設施（&#34;定期貸款 B 設施&#34;），該定期貸款 B 設施是對 800 百萬美元高級擔保定期貸款&#34;A&#34;設施（&#34;定期貸款 A 設施&#34;，與定期貸款 B 設施合稱為&#34;定期貸款設施&#34;）和 600 百萬美元高級擔保循環信貸設施的補充，BioMarin 預計將在收購中進入該循環信貸設施（&#34;新循環信貸設施&#34;，與定期貸款設施合稱為&#34;新高級擔保信貸設施&#34;）。</p>
<p>BioMarin 計劃將債券發行的淨收益與定期貸款設施的借款和手頭現金一起，用於支付與收購相關的對價及相關費用，借款於新高級擔保信貸設施，以及債券的發行。公司還可能在新循環信貸設施下借款最多 1.5 億美元以支付這些費用和支出。</p>
<p>債券發行的總收益將在發行結束時存入一個託管賬户，待收購完成。如果收購未能在 2026 年 12 月 19 日或之前完成，或在發生某些其他事件時，BioMarin 將被要求以債券初始發行價格的 100% 加上自發行之日起應計未付利息的贖回價格贖回所有債券，或至最近支付或提供利息的日期，但不包括特別強制贖回日期。</p>
<p>債券將由 BioMarin 的某些子公司共同和分別擔保，這些子公司將在新高級擔保信貸設施下擔保義務，包括在收購結束後，Amicus 及其某些子公司將擔保新高級擔保信貸設施下的義務。</p>
<p>債券的契約預計將包含慣常的約定，其中包括在某些例外情況下，限制 BioMarin 及其子公司承擔額外債務、支付股息、進行某些其他限制性支付、承擔擔保債務、處置資產、進行合併和收購或出售或轉讓其全部或大部分資產的能力。</p>
<p>債券將不會根據 1933 年證券法（&#34;證券法&#34;）或任何州或其他證券法進行註冊，且在沒有有效註冊聲明或適用的註冊豁免的情況下，可能不會在美國提供或出售。因此，債券的發行僅適用於有限數量的被合理認為是&#34;合格機構買家&#34;（根據證券法第 144A 條的定義）或根據證券法第 S 條在美國以外的非美國人士。債券將受到轉讓和轉售的限制，除非符合證券法的註冊要求或根據豁免進行轉讓，並遵守任何州或其他適用的證券法。</p>
<p>本新聞稿僅供信息參考，不構成或不形成購買、獲取、認購、出售或以其他方式處置任何證券的要約、邀請或要約的部分，也不構成在任何司法管轄區內根據擬議交易或其他情況的投票或批准的徵求，也不應在任何司法管轄區內違反適用法律進行證券的銷售、發行或轉讓。本新聞稿包含有關債券即將發行的信息，且無法保證該發行將完成。債券的發行僅可通過發行備忘錄進行。</p>
<p><strong>關於 BioMarin</strong></p>
<p>BioMarin 是一家領先的全球罕見疾病生物技術公司，專注於為生活在基因定義條件下的人們提供藥物。公司成立於 1997 年，總部位於加利福尼亞州聖拉斐爾，擁有創新的良好記錄，擁有八種商業療法和強大的臨牀及臨牀前管線。BioMarin 採用獨特的藥物發現和開發方法，旨在釋放基因科學的全部潛力，追求具有深遠影響的類別定義藥物。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含關於擬議的票據發行、新的高級擔保信貸設施的簽署、生物瑪琳（BioMarin）計劃發行票據及預計收益用途的前瞻性聲明。這些前瞻性聲明是預測，涉及風險和不確定性，因此實際結果可能與這些聲明有重大差異。這些風險和不確定性包括但不限於完成擬議的票據發行、新的高級擔保信貸設施和收購的時間，以及這些交易可能無法完成的風險，以及生物瑪琳在證券交易委員會的備案文件中詳細列出的因素，包括但不限於在生物瑪琳截至 2025 年 9 月 30 日的季度報告（Form 10-Q）中 “風險因素” 標題下包含的因素，這些因素可能會在後續報告中更新。投資者被敦促不要過度依賴前瞻性聲明，這些聲明僅在本日期有效。生物瑪琳沒有義務，並明確聲明不承擔更新或更改任何前瞻性聲明的義務，無論是由於新信息、未來事件還是其他原因，法律要求的情況除外。</p>
<p>BioMarin® 是生物瑪琳製藥公司（BioMarin Pharmaceutical Inc.）的註冊商標。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>聯繫人：</strong></td>
<td></td>
</tr>
<tr>
<td>投資者</td>
<td>媒體</td>
</tr>
<tr>
<td><em>Traci McCarty</em></td>
<td><em>Erin Rau</em></td>
</tr>
<tr>
<td><em>生物瑪琳製藥公司</em></td>
<td><em>生物瑪琳製藥公司</em></td>
</tr>
<tr>
<td><em>(415) 455-7558</em></td>
<td>(925) 683-9622</td>
</tr>
</tbody>
</table>
<p>來源：生物瑪琳製藥公司（BioMarin Pharmaceutical Inc.）</p>

紐交所高增長板生物技術指數 ETF - First Trust

2 倍做多納斯達克生物技術 ETF - ProShares

動態生物技術與基因組 ETF - Invesco

<p>拜瑪林製藥（BioMarin Pharmaceutical Inc.）計劃發行 8.5 億美元的 2034 年到期高級無擔保債券，並已啓動一項 20 億美元的高級擔保定期貸款的聯合安排，以支持其收購 Amicus Therapeutics。所得款項將用於收購及相關費用。該債券將由某些子公司提供擔保，並受到轉讓限制。此公告僅為信息性內容，不構成出售證券的要約</p>

<p>, /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (&#34;BioMarin&#34;) announced today that it intends to offer, subject to market and other conditions, $850 million of senior unsecured notes due 2034 (the &#34;Notes&#34;).</p>
<div class="lb-trans"><p>/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)（&#34;BioMarin&#34;）今天宣佈，計劃在市場和其他條件允許的情況下，發行 8.5 億美元的 2034 年到期的高級無擔保債券（&#34;債券&#34;）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/534018/BioMarin_Pharmaceutical_Inc_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/534018/BioMarin_Pharmaceutical_Inc_Logo.jpg"/></p>
<p>BioMarin also announced that, in connection with the pending acquisition (the &#34;Acquisition&#34;) of Amicus Therapeutics, Inc. (&#34;Amicus&#34;), it launched the syndication of a new $2 billion senior secured term loan &#34;B&#34; facility (the &#34;Term Loan B Facility&#34;), which Term Loan B Facility is in addition to a $800 million senior secured term loan &#34;A&#34; facility (the &#34;Term Loan A Facility&#34; and, together with the Term Loan B Facility, the &#34;Term Facilities&#34;), and a $600 million senior secured revolving credit facility into which BioMarin expects to enter in connection with the Acquisition (the &#34;New Revolving Facility&#34; and, together with the Term Facilities, the &#34;New Senior Secured Credit Facilities&#34;).</p>
<div class="lb-trans"><p>BioMarin 還宣佈，針對即將收購 Amicus Therapeutics, Inc.（&#34;Amicus&#34;）的交易（&#34;收購&#34;），啓動了一項新的 20 億美元高級擔保定期貸款&#34;B&#34;設施（&#34;定期貸款 B 設施&#34;），該定期貸款 B 設施是對 800 百萬美元高級擔保定期貸款&#34;A&#34;設施（&#34;定期貸款 A 設施&#34;，與定期貸款 B 設施合稱為&#34;定期貸款設施&#34;）和 600 百萬美元高級擔保循環信貸設施的補充，BioMarin 預計將在收購中進入該循環信貸設施（&#34;新循環信貸設施&#34;，與定期貸款設施合稱為&#34;新高級擔保信貸設施&#34;）。</p>
</div><p>BioMarin intends to use the net proceeds from the offering of the Notes, together with borrowings under the Term Facilities and cash on hand, to fund the consideration payable in connection with the Acquisition and related fees and expenses in connection with the Acquisition, the borrowings under the New Senior Secured Credit Facilities, and the issuance of the Notes. The company may also borrow up to $150 million under the New Revolving Facility to pay such fees and expenses.</p>
<div class="lb-trans"><p>BioMarin 計劃將債券發行的淨收益與定期貸款設施的借款和手頭現金一起，用於支付與收購相關的對價及相關費用，借款於新高級擔保信貸設施，以及債券的發行。公司還可能在新循環信貸設施下借款最多 1.5 億美元以支付這些費用和支出。</p>
</div><p>Gross proceeds from the issuance of the Notes will be deposited into an escrow account at the closing of the Offering, pending consummation of the Acquisition. In the event that the Acquisition is not completed on or prior to December 19, 2026, or upon the occurrence of certain other events, BioMarin will be required to redeem all of the Notes at a redemption price equal to 100% of the initial issue price of the Notes plus accrued and unpaid interest from the date of issuance, or the most recent date to which interest has been paid or provided for, to but excluding the special mandatory redemption date.</p>
<div class="lb-trans"><p>債券發行的總收益將在發行結束時存入一個託管賬户，待收購完成。如果收購未能在 2026 年 12 月 19 日或之前完成，或在發生某些其他事件時，BioMarin 將被要求以債券初始發行價格的 100% 加上自發行之日起應計未付利息的贖回價格贖回所有債券，或至最近支付或提供利息的日期，但不包括特別強制贖回日期。</p>
</div><p>The Notes will be jointly and severally guaranteed by certain of BioMarin's subsidiaries that will guarantee the obligations under the New Senior Secured Credit Facilities, including, after the closing of the Acquisition, Amicus and certain of its subsidiaries that will guarantee the obligations under the New Senior Secured Credit Facilities.</p>
<div class="lb-trans"><p>債券將由 BioMarin 的某些子公司共同和分別擔保，這些子公司將在新高級擔保信貸設施下擔保義務，包括在收購結束後，Amicus 及其某些子公司將擔保新高級擔保信貸設施下的義務。</p>
</div><p>The indenture governing the Notes is expected to contain customary covenants that, among other things, restrict, with certain exceptions, the ability of each of BioMarin and its subsidiaries to incur additional debt, pay dividends, make certain other restricted payments, incur debt secured by liens, dispose of assets, engage in consolidations and mergers or sell or transfer all or substantially all of its assets.</p>
<div class="lb-trans"><p>債券的契約預計將包含慣常的約定，其中包括在某些例外情況下，限制 BioMarin 及其子公司承擔額外債務、支付股息、進行某些其他限制性支付、承擔擔保債務、處置資產、進行合併和收購或出售或轉讓其全部或大部分資產的能力。</p>
</div><p>The Notes will not be registered under the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), or any state or other securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from the registration requirements of or in a transaction not subject to the Securities Act and any state or other applicable securities laws. Accordingly, the offering of the Notes is available only to a limited number of persons who are either (1) reasonably believed to be &#34;qualified institutional buyers&#34; as defined in Rule 144A under the Securities Act or (2) non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act. The Notes will be subject to restrictions on transferability and resale and may not be transferred or resold except in compliance with the registration requirements of the Securities Act or pursuant to an exemption therefrom and in compliance with any state or other applicable securities laws.</p>
<div class="lb-trans"><p>債券將不會根據 1933 年證券法（&#34;證券法&#34;）或任何州或其他證券法進行註冊，且在沒有有效註冊聲明或適用的註冊豁免的情況下，可能不會在美國提供或出售。因此，債券的發行僅適用於有限數量的被合理認為是&#34;合格機構買家&#34;（根據證券法第 144A 條的定義）或根據證券法第 S 條在美國以外的非美國人士。債券將受到轉讓和轉售的限制，除非符合證券法的註冊要求或根據豁免進行轉讓，並遵守任何州或其他適用的證券法。</p>
</div><p>This press release is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. This press release contains information about the pending offering of the Notes, and there can be no assurance that the offering will be completed. The offering of the Notes may be made only by means of an offering memorandum.</p>
<div class="lb-trans"><p>本新聞稿僅供信息參考，不構成或不形成購買、獲取、認購、出售或以其他方式處置任何證券的要約、邀請或要約的部分，也不構成在任何司法管轄區內根據擬議交易或其他情況的投票或批准的徵求，也不應在任何司法管轄區內違反適用法律進行證券的銷售、發行或轉讓。本新聞稿包含有關債券即將發行的信息，且無法保證該發行將完成。債券的發行僅可通過發行備忘錄進行。</p>
</div><p><strong>About BioMarin</strong></p>
<div class="lb-trans"><p><strong>關於 BioMarin</strong></p>
</div><p>BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.</p>
<div class="lb-trans"><p>BioMarin 是一家領先的全球罕見疾病生物技術公司，專注於為生活在基因定義條件下的人們提供藥物。公司成立於 1997 年，總部位於加利福尼亞州聖拉斐爾，擁有創新的良好記錄，擁有八種商業療法和強大的臨牀及臨牀前管線。BioMarin 採用獨特的藥物發現和開發方法，旨在釋放基因科學的全部潛力，追求具有深遠影響的類別定義藥物。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements about the proposed offering of the Notes, the entry into the New Senior Secured Credit Facilities, BioMarin's intention to issue the Notes and the expected use of proceeds. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others, the timing to consummate the proposed Notes offering, New Senior Secured Credit Facilities and Acquisition, and the risk that such transactions may not close, as well as those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption &#34;Risk Factors&#34; in BioMarin's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.</p>
<div class="lb-trans"><p>本新聞稿包含關於擬議的票據發行、新的高級擔保信貸設施的簽署、生物瑪琳（BioMarin）計劃發行票據及預計收益用途的前瞻性聲明。這些前瞻性聲明是預測，涉及風險和不確定性，因此實際結果可能與這些聲明有重大差異。這些風險和不確定性包括但不限於完成擬議的票據發行、新的高級擔保信貸設施和收購的時間，以及這些交易可能無法完成的風險，以及生物瑪琳在證券交易委員會的備案文件中詳細列出的因素，包括但不限於在生物瑪琳截至 2025 年 9 月 30 日的季度報告（Form 10-Q）中 “風險因素” 標題下包含的因素，這些因素可能會在後續報告中更新。投資者被敦促不要過度依賴前瞻性聲明，這些聲明僅在本日期有效。生物瑪琳沒有義務，並明確聲明不承擔更新或更改任何前瞻性聲明的義務，無論是由於新信息、未來事件還是其他原因，法律要求的情況除外。</p>
</div><p>BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.</p>
<div class="lb-trans"><p>BioMarin® 是生物瑪琳製藥公司（BioMarin Pharmaceutical Inc.）的註冊商標。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contacts:</strong></td>
<td></td>
</tr>
<tr>
<td>Investors</td>
<td>Media</td>
</tr>
<tr>
<td><em>Traci McCarty</em></td>
<td><em>Erin Rau</em></td>
</tr>
<tr>
<td><em>BioMarin Pharmaceutical Inc.</em></td>
<td><em>BioMarin Pharmaceutical Inc.</em></td>
</tr>
<tr>
<td><em>(415) 455-7558</em></td>
<td>(925) 683-9622</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>聯繫人：</strong></td>
<td></td>
</tr>
<tr>
<td>投資者</td>
<td>媒體</td>
</tr>
<tr>
<td><em>Traci McCarty</em></td>
<td><em>Erin Rau</em></td>
</tr>
<tr>
<td><em>生物瑪琳製藥公司</em></td>
<td><em>生物瑪琳製藥公司</em></td>
</tr>
<tr>
<td><em>(415) 455-7558</em></td>
<td>(925) 683-9622</td>
</tr>
</tbody>
</table>
</div><p>SOURCE BioMarin Pharmaceutical Inc.</p>
<div class="lb-trans"><p>來源：生物瑪琳製藥公司（BioMarin Pharmaceutical Inc.）</p>
</div>

BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility | BMRN Stock News

StockTitan

生物科技 ETF - VanEck Vectors

標普生物技術 ETF - SPDR

拜瑪林制藥

基因改革 ETF - ARK

Invesco Nasdaq Biotechnology ETF

納斯達克生物科技指數 ETF - iShares Nasdaq

美國制藥 ETF - iShares

醫藥突破 ETF - ALPS

拜瑪林製藥宣佈計劃進行高級票據的私人發售，併為新的高級擔保定期貸款融資進行銀團 | BMRN 股票新聞